BR0109194A - Método para preparar claritromicina em cristais da forma ii - Google Patents
Método para preparar claritromicina em cristais da forma iiInfo
- Publication number
- BR0109194A BR0109194A BR0109194-8A BR0109194A BR0109194A BR 0109194 A BR0109194 A BR 0109194A BR 0109194 A BR0109194 A BR 0109194A BR 0109194 A BR0109194 A BR 0109194A
- Authority
- BR
- Brazil
- Prior art keywords
- clarithromycin
- sym
- oxime
- crystals
- trimethylsilyl
- Prior art date
Links
- 229960002626 clarithromycin Drugs 0.000 title abstract 7
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title abstract 7
- 239000013078 crystal Substances 0.000 title abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 3
- 229930006677 Erythromycin A Natural products 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 229960003276 erythromycin Drugs 0.000 abstract 2
- LKGCPYOBWLSCTK-UHFFFAOYSA-N methanesulfonic acid;trihydrate Chemical compound O.O.O.CS(O)(=O)=O LKGCPYOBWLSCTK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- KYTWXIARANQMCA-RWJQBGPGSA-N (3r,4s,5s,6r,7r,9r,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2 Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=NO)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-RWJQBGPGSA-N 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 1
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- 239000012022 methylating agents Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 125000003544 oxime group Chemical group 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
"MéTODO PARA PREPARAR CLARITROMICINA EM CRISTAIS DA FORMA II". Claritromicina de alta pureza em cristais da Forma II pode ser preparada facilmente com um alto rendimento por um processo que compreende as etapas de: proteger o grupo hidróxi da 9-oxima da 9-oxima de eritromicina A ou um seu sal com um grupo tropila e os grupos 2' - e 4"-hidróxi com grupos trimetil-silila; reagir 9-<sym>-tropil-oxima de 2',4"-<sym>bis-(trimetil-silil)-eritromicina A com um agente metilante; remover os grupos protetores e o grupo oxima de 9-<sym>-tropiloxima de 2',4"-<sym>-bis-(trimetil-silil)-6-<sym>-metil-eritromicina A, para obter claritromicina bruta; tratar a claritromicina bruta com ácido metano-sulfónico em uma mistura de um solvente orgânico miscível com água e água, para obter mesilato de claritromicina cristalino triidratado; e neutralizar o mesilato de claritromicina cristalino triidratado com solução aquosa de amónea, em uma mistura de um solvente orgânico miscível com água e água.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000013033A KR100361397B1 (ko) | 2000-03-15 | 2000-03-15 | 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법 |
KR10-2000-0069834A KR100367981B1 (ko) | 2000-11-23 | 2000-11-23 | 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물 |
PCT/KR2001/000394 WO2001068662A1 (en) | 2000-03-15 | 2001-03-14 | Method of preparing clarithromycin of form ii crystals |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0109194A true BR0109194A (pt) | 2003-02-11 |
Family
ID=36274127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0109194-8A BR0109194A (pt) | 2000-03-15 | 2001-03-14 | Método para preparar claritromicina em cristais da forma ii |
Country Status (15)
Country | Link |
---|---|
US (1) | US6515116B2 (pt) |
EP (2) | EP1469008B1 (pt) |
JP (1) | JP4119125B2 (pt) |
CN (1) | CN1193036C (pt) |
AT (2) | ATE297941T1 (pt) |
AU (1) | AU771825B2 (pt) |
BR (1) | BR0109194A (pt) |
CA (1) | CA2402201C (pt) |
DE (2) | DE60111438T2 (pt) |
ES (2) | ES2270226T3 (pt) |
HU (1) | HUP0300418A3 (pt) |
MX (1) | MXPA02008861A (pt) |
NZ (1) | NZ521184A (pt) |
RU (1) | RU2230748C2 (pt) |
WO (1) | WO2001068662A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
EP1313486A1 (en) * | 2000-02-29 | 2003-05-28 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
KR100367981B1 (ko) * | 2000-11-23 | 2003-01-14 | 한미약품공업 주식회사 | 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물 |
CA2403757A1 (en) * | 2000-03-28 | 2001-10-04 | Biochemie Gesellschaft M.B.H. | Granulated particles with masked taste |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
US20060083759A1 (en) * | 2002-07-17 | 2006-04-20 | Aleksander Resman | Stabilization of the profile of release of active substances from a formulation |
EP1638549A4 (en) | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
ES2221807B1 (es) * | 2003-06-24 | 2005-12-16 | Ercros Industrial, S.A. | Un procedimiento para la obtencion de claritromicina. |
WO2005009364A2 (en) * | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
AU2004258949B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
EP1648407A4 (en) * | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION |
US8758820B2 (en) * | 2003-08-11 | 2014-06-24 | Shionogi Inc. | Robust pellet |
WO2005016278A2 (en) | 2003-08-12 | 2005-02-24 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
WO2005023184A2 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
JP2007513869A (ja) * | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2008505124A (ja) * | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
WO2006081711A1 (fr) * | 2005-02-07 | 2006-08-10 | Zte Corporation | Méthode de contrôle de mesure entre systèmes et mesure entre fréquences |
WO2007015265A2 (en) * | 2005-05-24 | 2007-02-08 | Kopran Research Laboratories Ltd | A process for preparing 6,9-imino ether |
WO2007008537A2 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International, Limited | Nanoparticulate clarithromycin formulations |
WO2007036951A2 (en) * | 2005-08-31 | 2007-04-05 | Alembic Limited | Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
EP2030613A1 (en) | 2007-08-17 | 2009-03-04 | Abbott GmbH & Co. KG | Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics |
AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
JP5602748B2 (ja) | 2008-10-24 | 2014-10-08 | センプラ ファーマシューティカルズ,インコーポレイテッド | トリアゾール含有マクロライドを用いた生体防御 |
CN101787063B (zh) * | 2009-01-23 | 2012-12-19 | 刘力 | 抗感染药物及其制备和用途 |
US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
CN102724874B (zh) | 2009-09-10 | 2018-06-01 | 森普拉制药公司 | 治疗疟疾、结核病和mac疾病的方法 |
KR102006200B1 (ko) | 2010-03-22 | 2019-08-01 | 셈프라 파마슈티컬스, 인크. | 매크로라이드의 결정 형태들 및 그 용도들 |
ES2636948T3 (es) * | 2010-05-20 | 2017-10-10 | Cempra Pharmaceuticals, Inc. | Procesos para preparar macrólidos y cetólidos e intermediarios para los mismos |
JP6042334B2 (ja) | 2010-09-10 | 2016-12-14 | センプラ ファーマシューティカルズ,インコーポレイテッド | 疾患治療のための水素結合形成フルオロケトライド |
CA2868262A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
CN103897002A (zh) * | 2012-12-31 | 2014-07-02 | 菏泽市方明制药有限公司 | 一种粗品硫氰酸红霉素制备红霉素a9-肟的方法 |
CN103087130B (zh) * | 2013-02-06 | 2015-12-23 | 浙江国邦药业有限公司 | 一种克拉霉素晶型转换方法 |
EP2968801B1 (en) | 2013-03-14 | 2018-09-26 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
EP2968384A4 (en) | 2013-03-15 | 2017-02-15 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60214796A (ja) * | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシン類の製法 |
US4670549A (en) * | 1985-03-18 | 1987-06-02 | Taisho Pharmaceutical Co., Ltd. | Method for selective methylation of erythromycin a derivatives |
KR960000434B1 (ko) * | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
US5872229A (en) * | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
US5837829A (en) * | 1996-04-02 | 1998-11-17 | Abbott Laboratories | 9-oximesilyl erythromycin a derivatives |
US5858986A (en) * | 1996-07-29 | 1999-01-12 | Abbott Laboratories | Crystal form I of clarithromycin |
ATE272646T1 (de) * | 1996-07-29 | 2004-08-15 | Abbott Lab | Herstellung von kristallinen form ii von clarithromycin |
US5945405A (en) * | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
US5864023A (en) * | 1997-02-13 | 1999-01-26 | Abbott Laboratories | 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives |
IL135792A0 (en) * | 1997-12-01 | 2001-05-20 | Abbott Lab | 6-o-alkyl derivatives of erythronolide b |
US6258785B1 (en) * | 1998-12-02 | 2001-07-10 | Pfizer Inc. | Crystalline 9-E-(O-methyl)oxime of 11, 12-dideoxy-3-de(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyloxy)-6-O-methyl-12,11-(iminocarbonyl-(2-(3-(4-(3-pyridinyl)1H-imadazol-1-yl)propyl)hydrazono))-3-oxoerythromycin |
-
2001
- 2001-03-14 CA CA002402201A patent/CA2402201C/en not_active Expired - Fee Related
- 2001-03-14 AT AT01106198T patent/ATE297941T1/de not_active IP Right Cessation
- 2001-03-14 NZ NZ521184A patent/NZ521184A/en unknown
- 2001-03-14 AU AU42827/01A patent/AU771825B2/en not_active Ceased
- 2001-03-14 ES ES04013295T patent/ES2270226T3/es not_active Expired - Lifetime
- 2001-03-14 WO PCT/KR2001/000394 patent/WO2001068662A1/en active IP Right Grant
- 2001-03-14 CN CNB018096050A patent/CN1193036C/zh not_active Expired - Fee Related
- 2001-03-14 EP EP04013295A patent/EP1469008B1/en not_active Expired - Lifetime
- 2001-03-14 EP EP01106198A patent/EP1134229B1/en not_active Expired - Lifetime
- 2001-03-14 RU RU2002127591/04A patent/RU2230748C2/ru not_active IP Right Cessation
- 2001-03-14 DE DE60111438T patent/DE60111438T2/de not_active Expired - Lifetime
- 2001-03-14 MX MXPA02008861A patent/MXPA02008861A/es active IP Right Grant
- 2001-03-14 US US09/805,831 patent/US6515116B2/en not_active Expired - Fee Related
- 2001-03-14 ES ES01106198T patent/ES2242668T3/es not_active Expired - Lifetime
- 2001-03-14 DE DE60122791T patent/DE60122791T2/de not_active Expired - Lifetime
- 2001-03-14 HU HU0300418A patent/HUP0300418A3/hu unknown
- 2001-03-14 AT AT04013295T patent/ATE338053T1/de not_active IP Right Cessation
- 2001-03-14 JP JP2001567752A patent/JP4119125B2/ja not_active Expired - Fee Related
- 2001-03-14 BR BR0109194-8A patent/BR0109194A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20010039333A1 (en) | 2001-11-08 |
EP1469008A1 (en) | 2004-10-20 |
US6515116B2 (en) | 2003-02-04 |
HUP0300418A2 (hu) | 2003-06-28 |
RU2230748C2 (ru) | 2004-06-20 |
RU2002127591A (ru) | 2004-02-27 |
ATE297941T1 (de) | 2005-07-15 |
EP1134229A3 (en) | 2002-02-27 |
DE60122791D1 (de) | 2006-10-12 |
EP1469008B1 (en) | 2006-08-30 |
EP1134229B1 (en) | 2005-06-15 |
AU771825B2 (en) | 2004-04-01 |
ATE338053T1 (de) | 2006-09-15 |
DE60111438T2 (de) | 2006-05-18 |
HUP0300418A3 (en) | 2003-09-29 |
AU4282701A (en) | 2001-09-24 |
DE60111438D1 (de) | 2005-07-21 |
CA2402201C (en) | 2007-06-05 |
CN1429233A (zh) | 2003-07-09 |
EP1134229A2 (en) | 2001-09-19 |
JP4119125B2 (ja) | 2008-07-16 |
NZ521184A (en) | 2004-02-27 |
CA2402201A1 (en) | 2001-09-20 |
WO2001068662A1 (en) | 2001-09-20 |
ES2270226T3 (es) | 2007-04-01 |
CN1193036C (zh) | 2005-03-16 |
DE60122791T2 (de) | 2007-10-04 |
MXPA02008861A (es) | 2003-02-10 |
JP2004500398A (ja) | 2004-01-08 |
ES2242668T3 (es) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0109194A (pt) | Método para preparar claritromicina em cristais da forma ii | |
Nakamura et al. | Structure of coformycin, an unusual nucleoside of microbial origin | |
NL2004835C2 (en) | Process for extracting materials from biological material. | |
CN102917708B (zh) | 制备大环内酯和酮内酯及其中间体的方法 | |
BR0116377A (pt) | Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria | |
BRPI0806318B8 (pt) | sacarídeo capsular modificado, processo para modificar um sacarídeo, conjugado proteína sacarídea, molécula e composição farmacêutica | |
BRPI0520252A2 (pt) | método de desacilar sucralose-6-éster | |
BR9803010A (pt) | Composição compreendendo sìlica pirogenada, utilização de uma sìlica pirogenada, processo de tratamento cosmético e processo de maquilagem. | |
CA2386221A1 (en) | Compounds for protecting hydroxyls and methods for their use | |
BR0005488A (pt) | Processo para a preparação de carbonato de vinileno, e o uso do mesmo | |
BR0211534A (pt) | Clivagem redutiva do éster exocìclico de uk-2a ou seus derivados e produtos formados dos mesmos | |
FR2319374B1 (pt) | ||
KR880009960A (ko) | 화학적 화합물 | |
AR063484A1 (es) | Sal de acido p-toluensulfonico de 5-amino-3-(2'-o-acetil-3'-desoxi-beta-d-ribofuranosil)-3h-tiazol[4, 5-d]pirimidin-2-ona, metodos para la preparacion de la misma y de sus intermediarios de sintesis, una composicion farmaceutica que la comprende y su uso en el tratamiento de infecciones virales y ca | |
HUP0104600A2 (hu) | Új intermedierek és eljárás azokból makrolid antibiotikum előállítására | |
KR890014128A (ko) | 황산염화된 k5 항원 및 황산염화된 k5 항원 단편물 | |
KR880007740A (ko) | 마크롤리드 화합물, 그의 제법 및 그의 용도 | |
BR0208367A (pt) | Composição farmacêutica de tratamento de infecções oculares por aplicação local, processo de preparação de uma composição farmacêutica de colìrio, e, utilização de azitromicina | |
Araki et al. | Structure of a triphosphonopentaosylceramide containing 4-O-methyl-N-acetylglucosamine from the skin of the sea hare, Aplysia kurodai. | |
KR920701229A (ko) | 에리트로마이신 유도체 | |
Hara et al. | Solid‐phase synthesis of fluorinated analogues of glycosyl 1‐phosphate repeating structures from Leishmania using the phosphoramidite method | |
CO5190679A1 (es) | Sal disfosfato de un derivado de 4"-sustituido-9-desoxo- 9a-aza-9a-homoeritromicina y su composicion farmaceutica | |
KR890005138A (ko) | 사카라이드 유도체 | |
PT1181298E (pt) | Novas 8a-e 9a-lactamas de 15 membros. | |
Borodkin et al. | Synthesis of oligomeric phosphono analogues of Leishmania lipophosphoglycan fragments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |